Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Vertex Pharmaceuticals Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income
Stock-based compensation expense
Depreciation expense
Deferred income taxes
(Gains) losses on equity securities
Increase (decrease) in fair value of contingent consideration
Other non-cash items, net
Accounts receivable, net
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Other liabilities
Changes in operating assets and liabilities
Adjustments to reconcile net income to net cash provided by operating activities
Net cash provided by operating activities
Purchases of available-for-sale debt securities
Sales and maturities of available-for-sale debt securities
Purchases of property and equipment
Sale of equity securities
Investment in equity securities and notes receivable
Payments related to finite-lived intangible assets
Payment to acquire business, net of cash acquired
Net cash (used in) provided by investing activities
Issuances of common stock under benefit plans
Repurchases of common stock
Payments in connection with common stock withheld for employee tax obligations
Payments on finance leases
Proceeds from finance leases
Other financing activities
Net cash provided by (used in) financing activities
Effect of changes in exchange rates on cash
Net increase (decrease) in cash, cash equivalents and restricted cash

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Vertex Pharmaceuticals Inc. net cash provided by operating activities increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Vertex Pharmaceuticals Inc. net cash (used in) provided by investing activities increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Vertex Pharmaceuticals Inc. net cash provided by (used in) financing activities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.